Canakinumab 150mg powder for solution for injection vials
NHS hospitals in England used £19,220,221 of indicative cost of Canakinumab 150mg powder for solution for injection vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 8.8% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Canakinumab 150mg powder for solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Canakinumab 150mg powder for solution for injection vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Royal Free London Nhs Foundation Trust | £16,698,560 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £1,499,098 |
| Leeds Teaching Hpls Nhs Trust | £645,307 |
| Alder Hey Childrens Nhs Foundation Trust | £158,845 |
| University College London Foundation Tr | £138,989 |
| Nottingham University Hospitals Trust | £79,422 |
The primary-care picture
Canakinumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Canakinumab medicine page.